| Issue |
Med Sci (Paris)
Volume 42, Number 3, Mars 2026
Chroniques génomiques
|
|
|---|---|---|
| Page(s) | 311 - 314 | |
| Section | Forum | |
| DOI | https://doi.org/10.1051/medsci/2026041 | |
| Published online | 20 March 2026 | |
Thérapies CAR-T in vivo : un progrès décisif
In vivo CAR-Ts, a significant breakthrough
Biologiste, généticien, Président d’Aprogène (association pour la promotion de la génomique), Marseille, France
*
This email address is being protected from spambots. You need JavaScript enabled to view it.
Abstract
Since 2017, the CAR-T ex vivo approach has been very successful for the treatment of B cell malignancies in spite of its complexity and cost. A novel method involves transforming T lymphocytes into CAR-T cells in situ (therefore, in vivo) and promises simplicity, speed and affordability. It also seems applicable to several autoimmune diseases and is currently the object of much activity and interest in academic and corporate environments.
© 2026 médecine/sciences – Inserm
Article publié sous les conditions définies par la licence Creative Commons Attribution License CC-BY (https://creativecommons.org/licenses/by/4.0), qui autorise sans restrictions l’utilisation, la diffusion, et la reproduction sur quelque support que ce soit, sous réserve de citation correcte de la publication originale.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.